Amorphical Announces Full Patient Enrollment in Phase 2 FDA Clinical Trial of AMOR-1 for the Treatment of Hypoparathyroidism

Novel Nano-Amorphous Calcium Carbonate Technology Platform Aims to Maintain Optimal Serum Calcium Levels Using Half the Elemental Calcium Dose of Conventional Treatments NES ZIONA, Israel, July 28, 2026 /PRNewswire/ -- Amorphical, a developer of nano-amorphous mineral-based pharmacologic...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.